Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rook

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
ACS Chemical Neuroscience|January 26, 2026
Discovery of 7-(Pyridin-3-yl)thieno[3,2-<i>b</i>]pyridine-5-carboxamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5Scott H Henderson, Anna E Ringuette, David L Whomble, et al.
ACS Pharmacology & Translational Science|August 23, 2021
Discovery of the First Selective M<sub>4</sub> Muscarinic Acetylcholine Receptor Antagonists with <i>in Vivo</i> Antiparkinsonian and Antidystonic EfficacyMark S Moehle, Aaron M Bender, Jonathan W Dickerson, et al.
ACS Medicinal Chemistry Letters|December 18, 2024
Discovery of 4-(5-Membered)Heteroarylether-6-methylpicolinamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5Elizabeth S Childress, Rory A Capstick, Katherine E Crocker, et al.
Journal of Medicinal Chemistry|December 12, 2024
Discovery of VU6024578/BI02982816: An mGlu<sub>1</sub> Positive Allosteric Modulator with Efficacy in Preclinical Antipsychotic and Cognition ModelsCarson W Reed, Jacob F Kalbfleisch, Jeremy A Turkett, et al.
ACS Medicinal Chemistry Letters|July 10, 2015
Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting SchizophreniaSusana Conde-Ceide, Carlos M Martínez-Viturro, Jesús Alcázar, et al.
Journal of Medicinal Chemistry|October 17, 2025
Optimization of Selective and CNS Penetrant Alkyne-Based TREK Inhibitors: The Discovery and Characterization of ONO-9517601 (VU6022856) and ONO-7927846 (VU6024391)Motoyuki Tanaka, Yoko Sekioka, Gakuji Hashimoto, et al.
ACS Medicinal Chemistry Letters|May 14, 2025
Discovery of Thieno[3,2-<i>b</i>]pyridine-5-carboxamide and 2,3-Difluorobenzamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5Katherine E Crocker, Scott H Henderson, Rory A Capstick, et al.
ACS Chemical Neuroscience|January 25, 2026
Discovery of VU6025733 (AG06827): A Highly Selective, Orally Bioavailable, and Structurally Distinct M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust <i>In Vivo</i> EfficacyAlison R Gregro, Charlotte Park, Madeline F Long, et al.
ACS Chemical Neuroscience|December 11, 2024
Discovery of VU0467319: an M<sub>1</sub> Positive Allosteric Modulator Candidate That Advanced into Clinical TrialsMichael S Poslunsey, Michael R Wood, Changho Han, et al.
Neuron|May 5, 2015
Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR CurrentsJerri M Rook, Zixiu Xiang, Xiaohui Lv, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
ACS Chemical Neuroscience|January 26, 2026
Discovery of 7-(Pyridin-3-yl)thieno[3,2-<i>b</i>]pyridine-5-carboxamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5Scott H Henderson, Anna E Ringuette, David L Whomble, et al.
ACS Pharmacology & Translational Science|August 23, 2021
Discovery of the First Selective M<sub>4</sub> Muscarinic Acetylcholine Receptor Antagonists with <i>in Vivo</i> Antiparkinsonian and Antidystonic EfficacyMark S Moehle, Aaron M Bender, Jonathan W Dickerson, et al.
ACS Medicinal Chemistry Letters|December 18, 2024
Discovery of 4-(5-Membered)Heteroarylether-6-methylpicolinamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5Elizabeth S Childress, Rory A Capstick, Katherine E Crocker, et al.
Journal of Medicinal Chemistry|December 12, 2024
Discovery of VU6024578/BI02982816: An mGlu<sub>1</sub> Positive Allosteric Modulator with Efficacy in Preclinical Antipsychotic and Cognition ModelsCarson W Reed, Jacob F Kalbfleisch, Jeremy A Turkett, et al.
ACS Medicinal Chemistry Letters|July 10, 2015
Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting SchizophreniaSusana Conde-Ceide, Carlos M Martínez-Viturro, Jesús Alcázar, et al.
Journal of Medicinal Chemistry|October 17, 2025
Optimization of Selective and CNS Penetrant Alkyne-Based TREK Inhibitors: The Discovery and Characterization of ONO-9517601 (VU6022856) and ONO-7927846 (VU6024391)Motoyuki Tanaka, Yoko Sekioka, Gakuji Hashimoto, et al.
ACS Medicinal Chemistry Letters|May 14, 2025
Discovery of Thieno[3,2-<i>b</i>]pyridine-5-carboxamide and 2,3-Difluorobenzamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5Katherine E Crocker, Scott H Henderson, Rory A Capstick, et al.
ACS Chemical Neuroscience|January 25, 2026
Discovery of VU6025733 (AG06827): A Highly Selective, Orally Bioavailable, and Structurally Distinct M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust <i>In Vivo</i> EfficacyAlison R Gregro, Charlotte Park, Madeline F Long, et al.
ACS Chemical Neuroscience|December 11, 2024
Discovery of VU0467319: an M<sub>1</sub> Positive Allosteric Modulator Candidate That Advanced into Clinical TrialsMichael S Poslunsey, Michael R Wood, Changho Han, et al.
Neuron|May 5, 2015
Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR CurrentsJerri M Rook, Zixiu Xiang, Xiaohui Lv, et al.
Pageof 11